Correlation Between Realtek Semiconductor and Synmosa Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Realtek Semiconductor and Synmosa Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Realtek Semiconductor and Synmosa Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Realtek Semiconductor Corp and Synmosa Biopharma, you can compare the effects of market volatilities on Realtek Semiconductor and Synmosa Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Realtek Semiconductor with a short position of Synmosa Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Realtek Semiconductor and Synmosa Biopharma.

Diversification Opportunities for Realtek Semiconductor and Synmosa Biopharma

-0.47
  Correlation Coefficient

Very good diversification

The 3 months correlation between Realtek and Synmosa is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding Realtek Semiconductor Corp and Synmosa Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Synmosa Biopharma and Realtek Semiconductor is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Realtek Semiconductor Corp are associated (or correlated) with Synmosa Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Synmosa Biopharma has no effect on the direction of Realtek Semiconductor i.e., Realtek Semiconductor and Synmosa Biopharma go up and down completely randomly.

Pair Corralation between Realtek Semiconductor and Synmosa Biopharma

Assuming the 90 days trading horizon Realtek Semiconductor Corp is expected to generate 1.93 times more return on investment than Synmosa Biopharma. However, Realtek Semiconductor is 1.93 times more volatile than Synmosa Biopharma. It trades about -0.01 of its potential returns per unit of risk. Synmosa Biopharma is currently generating about -0.07 per unit of risk. If you would invest  56,100  in Realtek Semiconductor Corp on September 13, 2024 and sell it today you would lose (3,400) from holding Realtek Semiconductor Corp or give up 6.06% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Realtek Semiconductor Corp  vs.  Synmosa Biopharma

 Performance 
       Timeline  
Realtek Semiconductor 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Realtek Semiconductor Corp are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable basic indicators, Realtek Semiconductor is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.
Synmosa Biopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Synmosa Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Realtek Semiconductor and Synmosa Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Realtek Semiconductor and Synmosa Biopharma

The main advantage of trading using opposite Realtek Semiconductor and Synmosa Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Realtek Semiconductor position performs unexpectedly, Synmosa Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Synmosa Biopharma will offset losses from the drop in Synmosa Biopharma's long position.
The idea behind Realtek Semiconductor Corp and Synmosa Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Complementary Tools

Money Managers
Screen money managers from public funds and ETFs managed around the world
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk